By Fineline Cube WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused CTDMO unit of WuXi Apptec, has entered into a licensing agreement with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. Facilitated by Johnson & Johnson Innovation, the deal allows Janssen Bio to utilize WuXi ATU’s TESSA technology and gain access to its proprietary clonal suspension HEK293 cell line. Financial details of the agreement were not disclosed.
Technology Details
TESSA technology is a high-performance system for manufacturing adeno-associated viral vectors (AAV). These vectors are capable of transducing a variety of cell and tissue types, making them a crucial tool in gene therapy. The technology can be scaled up to 200L, enabling a 10-fold higher yield and a significantly higher percentage of full AAV capsids. This results in greatly reduced overall AAV production costs compared to traditional plasmid-based AAV production systems.-Fineline Info & Tech